Machine learning is driving efforts to classify MS into distinct subtypes that may predict disease course, but two experts debate whether this will advance patient care.

Synthetic biology specialist GRO Biosciences is exploring strategic alternatives about six months after raising a series B ...

The bioengineered protein drugs market is experiencing a paradigm shift, with pharmaceutical and biotech companies leveraging ...